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Context. Data regarding prognostication of life expectancy in patients with
advanced cancer are of paramount importance to patients, families, and
clinicians. However, data regarding patients followed at home are lacking.
Objectives. The aim of this study was to evaluate the correlation between
various factors recorded at the beginning of home care assistance and survival.
Methods. A sample of consecutive patients admitted to two home care programs
was surveyed. A preliminary consensus was achieved as to the possible variables
easy to be recorded at home. These included age at the time of home care
admission, gender, residence, marital status, primary cancer diagnosis, Karnofsky
Performance Status (KPS) score, measures of systolic blood pressure and heart
rate, cyanosis, use of oxygen, and body temperature. The Edmonton Symptom
Assessment System was used to record the intensity of each symptom. Patients
were divided into two groups: patients with a survival of less than 10 days (short
survival) and patients with a survival of 10 days or more (medium-long survival).
Results. Three hundred seventy-four consecutive patients admitted to home
care programs were surveyed, of which 187 were male. The mean SD age was
72.1 12.7 years. The mean survival was 56.2 65 days. Mean survival was
71.5 67 days (287 patients) and 5.6 2.7 days (87 patients) in the short and
medium-long survival groups, respectively. No association between type of tumor
and survival was observed (P¼ 0.162). Univariate logistic regression analysis
revealed that male gender (P¼ 0.020), older age (P¼ 0.012), lower KPS scores
(P< 0.0005), systolic blood pressure less than 100 mmHg (P¼ 0.003), heart rate
greater than 100 beats per minute (P¼ 0.0006), delirium (P¼ 0.004), the use of
oxygen (P¼ 0.002), intensity of fatigue (P¼ 0.006), drowsiness (P< 0.0005),
anorexia (P< 0.0005), dyspnea (P< 0.0005), poor sense of well-being
(P< 0.0005), and distress score (P< 0.0005) were associated with a survival of less
than 10 days. Marital status, residence, cognitive function, fever, pain, depression,Address correspondence to: Sebastiano Mercadante,
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Vol. 45 No. 1 January 2013 57Prognostic Factors in Home Care Cancer Patientsand anxiety were not found to be significantly correlated with survival. In
a multiple logistic regression model, low systolic blood pressure and high heart
rate, gender, delirium, use of oxygen, KPS score, drowsiness, anorexia, and
dyspnea were significantly correlated with a shorter survival.
Conclusion. Low systolic blood pressure and high heart rate, male gender, poor
KPS score, anorexia, and dyspnea were correlated with a shorter survival. Moreover,
patients with low systolic blood pressure and high heart rate, male gender, poor
KPS score, and greater intensity of anorexia and dyspnea are more likely to die
within one week. The combination of physical symptoms from the Edmonton
Symptom Assessment System and other parameters included in this study, which
are simple to assess and are repeatable at home, should be further explored in
future studies to provide a simple tool for use with patients with advanced cancer
admitted to a home care program. J Pain Symptom Manage 2013;45:56e62.
 2013 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.Key Words
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Prognostication of life expectancy in pa-
tients with advanced cancer is of paramount
importance to patients, families, and clini-
cians. In the last several years, many studies
have been done to identify possible predictors
of survival in this population.1e5 However, data
regarding patients followed at home are lack-
ing. Most studies of home care have focused
on the probabilities of predicting a home
death6e8 rather than on survival. Indeed, com-
municating survival predictions is an impor-
tant part of cancer care, even at home, where
survival is assumed to be short.8 Investigating
possible factors associated with a shorter sur-
vival may help in planning communications
and making therapeutic decisions.
The Home Care-Italy group recently has
been established, with the intent to dissemi-
nate and implement information on cancer
patients followed at home, given the paucity
of existing data in this setting. As part of its sci-
entific program, this study was undertaken to
evaluate the correlation between various fac-
tors recorded at the beginning of home care
assistance and survival.Methods
Over a six-month period, we prospectively
collected the charts of consecutive patients ad-
mitted to two home care programs in L’Aquilaand Turin, which belong to the Home Care-
Italy group. These two programs, which are
representative of home care programs in Italy,
have been shown to provide a similar level of
assistance and have sufficient experience in
collecting scientific data.9 The patients
received home visits from physicians (two or
three weekly) and nurses (three to seven
weekly) and also have access to on-call visits
in case of need.
Ethics committee approval and informed
consent were obtained from the University of
Palermo. A preliminary consensus on the pos-
sible variables to be measured was achieved,
not only on the basis of the literature1e5 but
primarily based on the feasibility, simplicity,
and reproducibility of parameters to be mea-
sured at home (excluding biochemical data,
for instance). Consensus regarding the final
choices was reached after debating these issues
at an investigators’ meeting.
Patients were then followed at home accord-
ing to local policies and protocols. The follow-
ing information was collected (other than
survival time): age at the time of home care
admission, gender, residence, marital status,
primary cancer diagnosis, Karnofsky Perfor-
mance Status (KPS) score, systolic blood pres-
sure and heart rate, cyanosis, use of oxygen,
and body temperature. Symptom severity was
recorded using the Edmonton Symptom
Assessment System (ESAS). The ESAS is a vali-
dated and reliable assessment tool, commonly
Table 1
Primary Tumors
Tumor Type n (%)
Gastrointestinal 82 (21.9)
Lung 64 (17.1)
Genitourinary 46 (12.3)
Head and neck 42 (11.2)
Breast 35 (9.4)
Liver 28 (7.5)
Pancreas 26 (6.9)
Non-solid tumors 19 (5.1)
Sarcoma 8 (2.1)
Melanoma 7 (1.9)
Unknown 6 (1.6)
Others 11 (3.0)
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severity.10With theESAS, patients rate the sever-
ity of the following symptoms: pain, fatigue,
nausea, depression, anxiety, drowsiness, lack
of appetite, well-being, and shortness of breath.
The sum of the patient’s responses is the ESAS
distress score. Delirium was evaluated by the
clinical judgment of the home care palliative
care specialists and by the Mini-Mental State
Examination (scores less than 24of 30were con-
sidered to indicate that deliriumwas present).11
Patients were divided into two groups:
patients with a survival of less than 10 days
(short survival) and patients with a survival of
10 days or more (medium-long survival). This
was considered by the panel to be an important
interval to provide useful information in terms
of communication and therapeutic planning.
Statistical Analysis
Statistical analysis of quantitative and qualita-
tive data, including descriptive statistics, was
performed for all items. Continuous data are
expressed as mean SD, unless otherwise spec-
ified. One-way analysis of variance was conduct-
ed to analyze the possible relationship between
clinical variables and survival. Odds ratios and
their 95% CIs were calculated using the uni-
variate and multivariate model of logistic re-
gression analysis. Model performance was
evaluated using the Hosmer-Lemeshow test
for goodness of fit. The continuous variables
that were independently prognostic of survival
were assessed in univariate and multivariate lin-
ear regression models, and slope coefficients
with their SEs are presented. Data were ana-
lyzed by Epi Info software, version 6.0 (CDC,
Atlanta, GA) and SPSS software, version 14.0
(SPSS, Inc., Chicago, IL). All P-values were
two-sided, and P-values less than 0.05 were con-
sidered to indicate statistical significance.Results
Three hundred seventy-four consecutive
patients admitted tohomecareprograms inL’Aq-
uila and Turin were surveyed. The mean age was
72.1 12.7 years; 187patients weremale. Primary
tumor frequency is reported in Table 1.
Overall mean survival was 56.2 65 days.
Mean survival was 71.5 67 days (287 patients)
and 5.6 2.7 days (87 patients) in the shortand medium-long survival groups, respectively.
No association between type of tumor and sur-
vival was observed (P¼ 0.162). On univariate
logistic regression analysis, male gender
(P¼ 0.020), older age (P¼ 0.012), lower KPS
score (P< 0.0005), systolic blood pressure
less than 100 mmHg (P¼ 0.003), heart rate
more than 100 beats per minute
(P¼ 0.0006), delirium (P¼ 0.004), use of oxy-
gen (P¼ 0.002), intensity of fatigue
(P¼ 0.006), drowsiness (P< 0.0005), appetite
loss (P< 0.0005), dyspnea (P< 0.0005), poor
sense of well-being (P< 0.0005), and high dis-
tress score (P< 0.0005) (Tables 2 and 3) were
associated with a survival of less than 10 days.
Marital status, residence, cognitive function,
fever, pain, depression, and anxiety were not
found to be significantly correlated with
survival.
In a multiple logistic regression model, low
systolic blood pressure and high heart rate,
gender, delirium, use of oxygen, poor KPS
score, drowsiness, appetite loss, and dyspnea
were significantly correlated with a shorter sur-
vival (Tables 2 and 3). The Hosmer-Lemeshow
goodness-of-fit test for the final model yielded
a P-value of 0.640, suggesting the model fits
the data well.Discussion
This is the first study to examine factors cor-
related with a short survival in patients with ad-
vanced cancer followed at home. It also was
a first attempt to identify some simple vari-
ables, easy to measure at home, that can be
evaluated in larger studies. Moreover, analysis
was based on intensity of symptoms, as
Table 2
Univariate and Multivariate Multiple Regression Analyses in Survival Groups
Variables
Survival $10 Days,
Mean (SD)
Survival <10 Days,
Mean (SD)
Univariate Regression
Analysis, Coefficient (SE); P
Multivariate Regression Analysis,
Coefficient (SE); P
Age (yr) 71.1 (13.1) 75.1 (10.9) 0.004 (0.002); 0.012 0.002 (0.001); 0.229
KPS score 47.5 (17.1) 35.1 (12.1) 0.008 (0.001); <0.0005 0.004 (0.001); 0.002
Pain 2.8 (2.6) 2.9 (2.8) 0.0007 (0.008); 0.933
Fatigue 6.5 (3.9) 7.7 (2.5) 0.016 (0.006); 0.006 0.0008 (0.006); 0.888
Nausea 1.5 (2.4) 1.9 (2.5) 0.011 (0.009); 0.209
Depression 3.8 (2.9) 4.4 (3.3) 0.011 (0.007); 0.124
Anxiety 3.2 (2.7) 3.8 (3.2) 0.013 (0.007); 0.095
Drowsiness 2.8 (2.7) 5.1 (2.9) 0.045 (0.007); <0.0005 0.021 (0.008); 0.011
Appetite loss 4.7 (3.1) 6.8 (3.1) 0.036 (0.006); <0.0005 0.025 (0.008); 0.0021
Well-being 5.1 (2.8) 6.5 (2.9) 0.029 (0.007); <0.0005 0.003 (0.010); 0.743
Dyspnea 2.0 (2.6) 3.9 (3.4) 0.037 (0.007); <0.0005 0.020 (0.007); 0.009
ESAS distress score 31.5 (14.8) 42.1 (16.1) 0.008 (0.001); <0.0005 0.0008 (0.002); 0.740
KPS¼ Karnofsky Performance Status score; ESAS¼ Edmonton Symptom Assessment System.
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mere presence or absence of symptoms.
Numerous factors have been found to be im-
plicated in short survival. A high level of symp-
tom burden is likely to be associated with
a shorter survival12 as well as other signs,Table 3
Univariate and Multivariate Logistic Regre
Variables
Survival $10 Days
(n¼ 287), n (%)
Survival <10 Days
(n¼ 87), n (%) Reg
Gender
Male 134 (46.7) 53 (60.9)
Female 153 (53.3) 34 (39.1)
Residence
Town 199 (69.8) 53 (60.9)
Village 86 (30.2) 34 (39.1)
Delirium
Yes 7 (2.6) 9 (10.7) 4
No 263 (97.4) 75 (89.3)
Fever
Yes 10 (3.6) 5 (6.0)
No 266 (96.4) 79 (94.0)
Heart rate
$100 23 (8.1) 19 (22.1)
<100 262 (91.9) 67 (77.9)
Cyanosis
Yes 7 (2.4) 5 (5.7)
No 280 (97.6) 82 (94.2)
Use of oxygen
Yes 27 (9.4) 19 (21.8)
No 260 (90.6) 68 (78.2)
Hospitalization
Yes 23 (19.8) 2 (8.3)
No 93 (80.2) 22 (91.7)
Systolic blood pressure
<100 26 (9.0) 18 (20.7)
$100 261 (91.0) 69 (79.3)
Marital status
Divorced 8 (2.8) 0 (0.0)
Single 20 (7.0) 4 (4.7)
Widow 75 (26.1) 27 (31.8)
Married 184 (64.1) 54 (63.5)
OR¼ odds ratio.such as tachycardia and low systolic blood pres-
sure, which are indirect signs of autonomic
dysfunction. All factors implicated in respira-
tory function (dyspnea, cyanosis, the use of ox-
ygen) were associated with a shorter survival,
whereas psychological factors or pain intensityssion Analyses in Survival Groups
Univariate Logistic
ression, OR (95% CI); P
Multivariate Logistic
Regression, OR (95% CI); P
1.8 (1.1e2.9); 0.02 1.9 (1.1e3.3); 0.024
0.7 (0.4e1.1); 0.104
.51 (1.5e13.9); 0.004 3.8 (1.3e11.6); 0.018
1.7 (0.5e5.6); 0.350
3.2 (1.7e6.2); 0.0006 3.1 (1.4e6.9); 0.005
2.4 (0.7e7.8); 0.125
2.7 (1.4e5.1); 0.002 2.3 (1.1e4.9); 0.038
0.4 (0.1e1.7); 0.181
2.6 (1.3e5.3); 0.003 2.7 (1.6e5.9); 0.002
0.9 (0.6e1.4); 0.754
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sis, low systolic blood pressure and high heart
rate, gender, delirium, the use of oxygen,
lower KPS scores, drowsiness, appetite loss,
and dyspnea were confirmed to be correlated
with a survival of less than 10 days. These fac-
tors are meaningful and easy to assess.
Males had a shorter survival. This result was
not expected and only can be explained by
later admission to home care in comparison
with women, rather than to diseases prevalent
in males, as no differences were found in pri-
mary diagnosis. Of interest, in a multiple logis-
tic regression model, the ESAS distress score
did not influence survival, underscoring the
relevance of some specific physical symptoms
over others. Finally, it is likely that some pa-
rameters, which were found altered only in
a small number of patients, might possibly in-
terfere with survival when analyzed in a larger
sample of patients. Thus, these parameters
should be better assessed in a prognostic
model in studies with greater numbers of
home care cancer patients.
Studies of cancer patients admitted to home
care programs are lacking in the literature, so
we were not able to make any comparisons.
Many studies published in the last few years,
performed in different settings, have allowed
the development of various tools to estimate
survival, such as clinical prediction of survival,
principally based on experience and subject to
many biases; the Palliative Prognostic Score;
the Palliative Performance Index; and others.
Some of these tools require biological
markers, which are unreliable or difficult to
perform at home.11
Recent reviews provide information about
predicting survival in patients with advanced
disease in the general population.2e4 Irrespec-
tive of the underlying type of malignancy, most
patients with advanced cancer experience
a prolonged period of gradual decline and
then a short phase of accelerated decline in
the last weeks of life. The main indicators of
this final phase are poor performance status;
weight loss; symptoms such as appetite loss,
breathlessness, or confusion; and abnormali-
ties on some laboratory parameters, including
high white cell count, lymphopenia, hypoalbu-
minemia, and elevated lactate dehydrogenase
or C-reactive protein.4,5,13 Recently, a two-week
survival prognostic model that incorporatedboth biochemical markers and the presence
of appetite loss, dyspnea, and edema14 was
used in a palliative care unit.
Prognostic methods also have been reported,
based only on clinical signs. The ESAS, which
has been used to assess symptom burden
and monitor changes after clinical interven-
tions,15,16 was used in the present study, and
as it is validated in different languages, it may
be useful for home care teams as ameans of sur-
vival prediction. Recently, ESAS scores have
been found to worsen in the last four weeks be-
fore death compared with those in the previous
months.17 Shortness of breath has been associ-
ated with a higher risk of dying in an acute
palliative care unit but was unevaluable onmul-
tivariate analysis because of a large number of
missing data. The observation that tachypnea
and oxygen use were both significant highlights
the prognostic importance of respiratory fail-
ure and its accompanying signs.11 However,
these data were predictors of inpatient mortal-
ity rather than length of survival.
In a recent study, fatigue, shortness of
breath, lack of appetite, and feeling sad, as as-
sessed by the M. D. Anderson Symptom Inven-
tory, were found to be independent prognostic
factors for survival time in hospitalized cancer
patients, with a mean survival of 49 days.18 Sim-
ilarly, appetite loss, drowsiness, dyspnea, and
fatigue were found to be associated with time
to death, with a mean survival of 36 days.12
These data were obtained, however, in the hos-
pital or outpatient clinic setting, and symp-
toms were evaluated at the last assessment in
the palliative care clinic, which was, on aver-
age, about five weeks before death.
Of interest, psychological symptoms were
not significantly associated with survival, as ob-
served in the present study performed at
home. This finding was expected, possibly be-
cause psychological symptoms are persistent
in the different phases of disease, even when
physical symptom burden is less prominent.
Similar results have been reported in recent
studies using the ESAS.12,19 The ESAS, how-
ever, may not be a reliable or specific measure
for psychological symptoms.20 In another
study, for example, depressive symptoms were
studied longitudinally using the Beck Depres-
sion Inventory, a validated measure for depres-
sion. In contrast to the flat pattern found with
the ESAS, depression increased in a curvilinear
Vol. 45 No. 1 January 2013 61Prognostic Factors in Home Care Cancer Patientsfashion toward the end of life.21 The limited
psychometric evidence supports the need for
further ESAS validation studies.22
Surprisingly, hemodynamic values have never
been included in previous prognostic models,
despite the likelihood that these parameters
aremeaningfully associated with a short survival
and are worthy of appropriate assessment. Of
interest, tachycardia was associated with death
in an acute palliative care unit.11
This study has obvious limitations, given the
exploratory nature of this approach and the
limited number of patients recruited in two
home care programs. These findings need fur-
ther evaluation in larger prospective studies.
However, the findings of this trial may provide
useful information for new prognostic models
to be tested and validated for use with those
patients followed at home.
In conclusion, information about survival in
patients with advanced cancer followed at
home is of the utmost importance to patients,
families, and clinicians, and assessment of sim-
ple parameters associated with short survival
may be helpful. Low systolic blood pressure
and high heart rate, gender, low KPS score,
appetite loss, and dyspnea were correlated
with a survival of less than 10 days. The combi-
nation of physical symptoms of the ESAS and
other parameters included in this study, which
are simple to assess and repeatable at home,
should be further explored in future studies
with larger numbers of patients to construct
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